TORONTO, ONTARIO--(Marketwire -08/29/12)- Lorus Therapeutics Inc. (LOR.TO) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and ...

TORONTO, ONTARIO--(Marketwire - Mar 5, 2013) - Lorus Therapeutics Inc. (LOR.TO) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical ...

Lorus Therapeutics Inc. (LOR.TO) ("Lorus") is pleased to announce that it has completed today its previously announced public offering (the "Offering") of common shares of Lorus (the "Offered Shares") ...

Lois Walter shouldn't be alive today. The 78-year-old grandmother from Mapleton, Iowa, was diagnosed with pancreatic cancer, one of the deadliest, in July, 2002. Doctors gave her four to six months to ...

TORONTO, ONTARIO--(Marketwired - Oct 28, 2013) - Lorus Therapeutics Inc. (LOR.TO) ("Lorus" or the "Company), today announced the appointment of William Rice, Ph.D. as its Chief Executive Officer and ...

TORONTO, ONTARIO--(Marketwired - March 18, 2014) - Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Company") announced that Dr. Aiping Young is leaving her position as President and Chief Operating ...

Lorus Therapeutics Inc. has announced publication of scientific data from preclinical studies demonstrating the antitumor activity of its lead small interfering RNA (siRNA) candidate, siRNA-1284. The ...

TORONTO, July 15, 2014 /CNW/ - Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company") announces that its shareholders will be asked to approve (i) a change of the corporate name to "Aptose ...

Shares of Lorus Therapeutics Inc. jumped more than 20 per cent Monday after receiving approval from the U.S. Food and Drug Administration (FDA) for one of its key treatments. The FDA granted `orphan ...